ReviewBMC psychiatry2017
Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools.
Review in BMC psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04727827 (A Prospective Interventional Trial of Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Interventional Trial of Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of pharmacogenomics testing guiding on clinical outcomes in major depressive disorder: a systematic review and meta-analysis of RCT.BMC psychiatry · 2023Pooled it
- Article
- Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review.Frontiers in pharmacology · 2023Review
- The pharmacogenetics ofFrontiers in pharmacology · 2023Article
- A Guide to a Pharmacist-Led Pharmacogenetic Testing and Counselling Service in an Interprofessional Healthcare Setting.Pharmacy (Basel, Switzerland) · 2022Article
- Article
- Isobaric Tags for Relative and Absolute Quantitation Identification of Blood Proteins Relevant to Paroxetine Response in Patients With Major Depressive Disorder.Frontiers in psychiatry · 2022Article
- Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder.Psychiatry research · 2021Article
- Prescription Pattern of Antidepressants and the Potential for Personalized Medicine in the Qatari Population.Journal of personalized medicine · 2021Article
- "Novel Psychopharmacology for Depressive Disorders".Advances in experimental medicine and biology · 2021Review
- Drug-target-ADR Network and Possible Implications of Structural Variants in Adverse Events.Molecular informatics · 2020Article
- Pharmacogenetic Testing Options Relevant to Psychiatry in Canada: Options de tests pharmacogénétiques pertinents en psychiatrie au Canada.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020Review
- Article
- Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders.Heliyon · 2020Review
- Panacea, placebo or poison? Genetically guided treatment for depression.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2020Article
- The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.Molecular biology reports · 2020Review
- Using Pharmacogenomic Testing in Primary Care: Protocol for a Pilot Randomized Controlled Study.JMIR research protocols · 2019Article
- The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice.International journal of molecular sciences · 2019Review
- Pitfalls in Geriatric Prescribing: Antidepressants and Extreme Sedation.Case reports in medicine · 2019Article
- Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About half of people who take antidepressants do not respond and many experience adverse effects. These detrimental outcomes are in part a result of the impact of an individual's genetic profile on pharmacokinetics and pharmcodynamics. If known and made available to clinicians, this could improve decision-making and antidepressant therapy outcomes. This has spurred the development of numerous pharmacogenetic-based decision support tools. In this article, we provide an overview of pharmacogenetic decision support tools, with particular focus on tools relevant to antidepressants. We briefly describe the evolution and current state of antidepressant pharmacogenetic decision support tools in clinical practice, followed by the evidence-base for their use. Finally, we present a series of considerations for clinicians contemplating use of these tools and discuss the future of antidepressant pharmacogenetic decision support tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.